Kornimate/medical-research-clean huggingface dataset:
parasitism & covid19 vaccines: new challenge.

Conditions: Helminths Infection; Protozoan Infections

Summary: - parasitic infection is a serious public health problem throughout the world particularly in developing countries including egypt. the individuals infected with helminths are responding to the parasite infections by a specific th2 type innate and adaptive immune responses. the coronavirus disease 2019 pandemic has affected over 169 million people and caused the death of millions worldwide. covid vaccines with up to 95% of efficacy and effectiveness have been developed and approved by the food and drug administration (fda), usa. moreover, it's reported that vaccination against covid may lead to cytokine storm syndrome in some vaccinated people with release of large amounts of cytokines as (ifnγ, il-12, tnfα).

* parasitic infection is a serious public health problem throughout the world particularly in developing countries including egypt. * stool examination and cbc(complete blood count) are considered as the most easily, affordable and accessible diagnostic tool to suspect the presence of parasitic infection. * one of the most important laboratory findings in many helminthic and protozoan infections is the high rate of peripheral blood eosinophilia. giardia lamblia cause increased number of lymphocytes. * the individuals infected with helminths are responding to the parasite infections by a specific th2 type innate and adaptive immune responses. the th2 pattern cytokines predominate in long-term helminth infected individuals. * during chronic helminths infection, there is increased production of interleukin-4 (il-4) and interleukin-10 (il-10) as anti-inflammatory cytokines, as well as increased activation and expansion of eosinophils, mast cells and basophils. * in addition, ifnγ have an important inflammatory role in many protozoan parasites as cryptosporidium, microsporidia, entamoeba histolytica. * the coronavirus disease 2019 pandemic has affected over 169 million people and caused the death of millions worldwide. covid vaccines with up to 95% of efficacy and effectiveness have been developed and approved by the food and drug administration (fda), usa. * moreover, it's reported that vaccination against covid may lead to cytokine storm syndrome in some vaccinated people with release of large amounts of cytokines as (ifnγ, il-12, tnfα).

Eligibility criteria:
inclusion criteria: * vaccinated and non-vaccinated individuals with covid-19 vaccines who are known to have different parasitic infections (helminths and protozoan) and admitted to assiut city hospitals. exclusion criteria: * bleeding disorders that may alter cbc results.
intubation of obese patients in the operating room with or without bag-mask ventilation

Conditions: Morbid Obesity; Ventilation Therapy; Complications

Summary: the aim of the study is to answer a daily question in the operating room: what is the safest technique for intubation of severe/morbid obese patients (bmi 35 or more). there is a great heterogeneity of practices on the subject, so the principle is to determine a common practice to facilitate the management of these patients.

anesthesia consultation or pre-anesthesia visit: * screening for inclusion and non-inclusion criteria * patient information * collection of consent * inclusion d0 (day of inclusion): * before general anesthesia : collection of epidemiological data (history + clinical examinations) + randomization (arm a/not vent : intubation without ventilation or arm b/vent : intubation with ventilation) * general anesthesia : intubation according to randomization arm + collection primary endpoint + conduct of the intubation procedure + morbidity of the intubation procedure * after general anesthesia : collection of secondary endpoints + conduct of the intubation procedure + morbidity of the intubation procedure + intraoperative respiratory morbidity * post-interventional care room : collection of clinical parameters in the icu : postoperative morbidity + study discharge (hospital discharge)

Eligibility criteria:
inclusion criteria: * patient requiring general anesthesia with intubation for surgery or scheduled endoscopic procedures * age \> 18 years * with a bmi superior or equal to 35kg.m-² * patient having signed an informed consent non-inclusion criteria: * ambient air saturation \<90% * urgent surgery \< 24 hours * cardio-thoracic surgery * mask ventilation not possible (e.g. atcd, cervical irradiation, fixed mandible) * formal contraindication to mask ventilation (e.g. occlusive syndrome, non fasting patient, symptomatic gastroesophageal reflux untreated or persistent under treatment) * wish of the operator for high flow oxygen preoxygenation * wish of an intubation without curare by the operator * pregnant or breast-feeding women * protected adults (guardianship, curatorship or safeguard of justice) * participation in another randomized clinical research study concerning preoxygenation and relevant to the primary endpoint * absence of affiliation to the french social security system
microwave ablation simultaneously combined with lenavatinib for recurrent hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Microwave Ablation; Liver Cancer; Lenvatinib; Recurrent Tumor

Summary: this study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent hcc

microwave ablation (mwa) is available as the major curative treatments for early-stage recurrent hcc. lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. no study has evaluated mwa simultaneously combined lenvatinib for recurrent hcc. there needs further investigation to explore the efficacy and safety of the combination treatment. thus, the investigators carried out this randomized, multicenter, prospective trial study to find out it.

Eligibility criteria:
inclusion criteria: 1. primary hcc (bclc 0-b), and the pathological results is hepatocellular carcinoma； 2. recurrent hcc without any tumor related therapy； 3. tumor number ≤3； 4. tumor size ≤5cm; 5. good performance, kps≥90； 6. age：18-75 7. child-pugh a or b（score of the b level is no more than 7） 8. baseline laboratory examinations meet the criteria： leukocyte ≥3.0×109/l； blood platelet ≥75×109/l； hemoglobin ≥100g/l； alt、ast ≤ 3 x limit of normal（uln）； serum creatinine ≤ 1.5 x uln； prothrombin time \< uln+4 s；inr \< 1.5, albumin ≥30g/l ； total bilirubin ≤34mmol/l； exclusion criteria: 1. disagreeing to receive follow-up observation and participate the clinical study; 2. accompanying with a history of other malignancies; 3. accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus; 4. with extrahepatic metastasis or lymph metastasis; 5. receiving system therapy such as targeted therapy or immunotherapy; 6. receiving local therapy such as ablation or tace; 7. any of the following occurred within 12 months of the study: myocardial infarction, severe / unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack), pulmonary embolism; ongoing arrhythmia by nci-ctca standard ≥ 2, prolonged qtc interval (450 ms for males, and\> 470 ms for females; 8. other serious acute, chronic physiological or mental disorders or abnormal laboratory examination may increase the risk of participation in study treatment or may interfere with the interpretation of study findings or whom the investigator considers not fit;
comparison of diagnostic performances of 68ga-dotatate pet-ct and 18f-fdopa pet-ct in paragangliomas and pheochromocytomas evaluation

Conditions: Paragangliomas; Pheochromocytomas

Summary: 18f-fdopa pet-ct is currently the gold standard in the evaluation of pheochromocytomas and paragangliomas (pheo - pgl) since these tumors can also decarboxylate amino acids such as dihydroxyphenylalanine (dopa). this property is common to tumors of the apud system (amine precursor uptake and decarboxylation). in recent years, pet (positron emission tomography) imaging using peptide receptors has gained an increasing role in the management of nets. the use of somatostatin agonists, radiolabeled with gallium-68 (68ga) enables targeting of somatostatin receptors (sstrs) with a pet resolution. this has improved diagnosis of sstrs-expressing tumors, including pgls. in the present study, the investigators have chosen dotatate (nal3-octreotate) rather than other agonists (dotatoc and dotanoc), because of its higher affinity for sst2 which is the most overexpressed subtype in pheo/pgl. however, performances of 18f-fdopa pet-ct and 68ga-dotatate pet-ct have never been compared in this clinical setting.


Eligibility criteria:
inclusion criteria: age ≥ 18 * pheo or pgl: initial staging or restaging * reference imaging within the last 2 months: multiphasic cervico-thoracoabdominal ct scan, 18f-fdopa pet-ct and head and neck mri (if head and neck localization exclusion criteria: pregnant or breast-feeding woman
a study to evaluate the efficacy, safety, and tolerability of bms-986278 in participants with progressive pulmonary fibrosis

Conditions: Progressive Pulmonary Fibrosis

Summary: the purpose of this study is to evaluate the efficacy, safety, and tolerability of bms-986278 in participants with progressive pulmonary fibrosis.


Eligibility criteria:
inclusion criteria * diagnosis of interstitial lung disease (ild) with features consistent with progressive ild within 24 months prior to screening, and ≥ 10% extent of fibrosis on screening high-resolution computed tomography (hrct). * if on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening. * if not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening. * mycophenolate mofetil (mmf), mycophenolic acid (ma), azathioprine (aza), and tacrolimus are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. if not currently on mmf, ma, aza, or tacrolimus, participants must not have taken these medications within 28 days prior to screening. * traditional disease-modifying antirheumatic drug (dmards) (eg. methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. if not currently on traditional dmard, participants must not have taken these medications within 28 days prior to screening. * biologic dmards (eg. tnf blockers and il-1 inhibitors) and janus kinase inhibitors (jak inhibitors eg. tofacitinib, upadacitinib) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. if not currently on biologic dmard or jak inhibitor, participants must not have taken these medications within 28 days prior to screening. * women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test. * men who are sexually active with women of childbearing potential agree to use male barrier contraception. exclusion criteria * idiopathic pulmonary fibrosis with usual interstitial pneumonia (uip) verification at screening. * history of stroke or transient ischemic attack within 3 months prior to screening. * participants who exhibit symptoms of heart failure at rest. * participants who have a current malignancy or a previous malignancy in the past 5 years prior to screening, except for those who have a documented history of cured nonmetastatic squamous cell skin carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ. * use of systemic corticosteroids equivalent to prednisone \> 15 mg/day is not allowed within 4 weeks prior to screening and during the study. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: bms-986278 lpa1 antagonist pulmonary fibrosis interstitial lung disease rheumatoid arthritis connective tissue disorders sarcoidosis scleroderma fibrosis antifibrotic therapy
short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to determine whether or not smoked marijuana improves spasticity in patients with multiple sclerosis.

studies of cannabinoids for spasticity in ms have had mixed results but clinical studies have been small, generally not properly controlled, with results controversial, and difficult to interpret. recently, investigators in the uk and us tested the ability of cannabinoids to control spasticity and tremor symptoms of the ms-like disease, experimental allergic encephalomyelitis, in mice (baker et al, 2000). the authors found that four different cannabinoids quantitatively ameliorated both tremor and spasticity in diseased mice; thus providing rationale for patients' reports of the therapeutic effects of cannabis in the control of their ms symptoms. the present study will be a randomized, placebo-controlled, crossover design of 30 patients who will be assessed before and after treatment for 3 consecutive days (phase i), undergo washout-out for a total of 11 days, and then cross over to either the placebo or active treatment phase (phase ii), depending on what they received during phase i. at each study visit, patients will utilize a controlled puff procedure to help ensure stable intake (levin et al, 1989). comparisons: a single dose of 4% thc marijuana cigarette each day for 3 days will be compared to a placebo administered under the same dosing conditions for the relief of spasticity, drug tolerability, and changes in global functioning and quality of life indices.

Eligibility criteria:
inclusion criteria: * clinically definite or probable, laboratory-supported ms * complaints of spasticity and at least moderate increase in tone as evidenced by a score of \>= 2 on the modified ashworth scale at either the elbow, hip, or knee * if on disease-modifying therapy ("abc"), have been on a stable dose for at least six months * fluent in english * if not cannabis-naive, must refrain from smoking cannabis for two weeks prior to screening (confirmed by urinalysis) * if on either lioresal (baclofen) or tizanadine (zanaflex), have been on a stable dose for at least three months * \>=18 years of age exclusion criteria: * axis i psychiatric disorder especially depression or significant neurological disease other than ms as determined by the pi * recent history of active substance abuse defined as daily use for at least 14 days within the past month * drug use restrictions, eg, subjects on probation or parole, employment involving high risk to themselves and/or the public (airline pilot, bus driver, etc.) * any unstable medical health problem * any known pulmonary disorders, including tuberculosis, asthma, or copd * pregnant or nursing * require benzodiazepines to control spasticity * require high doses of analgesic medications on a daily basis

Keywords: multiple sclerosis cannabis spasticity tolerability
gait retraining to reduce joint loading, inflammation, and ptoa risk

Conditions: Anterior Cruciate Ligament Reconstruction

Summary: the purpose of this study is to determine changes to knee joint loading, biological markers, and cartilage structure following a novel active feedback gait retraining program in anterior cruciate ligament reconstructed patients.


Eligibility criteria:
inclusion criteria: * age 18-40 years * history of primary aclr with or without meniscal repair * full weight-bearing status * neutral to varus knee alignment * plans to remain in the area for at least 8 months. exclusion criteria: * kellgren-lawrence (kl) radiographic grade \> 2 * additional injury or surgery to the involved knee * bmi \>30 kg/m2 * use of walking, orthopedic, or prosthetic assistive device * pregnancy * inability to have mri
fgf-1 for topical administration for the treatment of diabetic or venous stasis ulcers

Conditions: Chronic Wounds; Diabetes; Venous Stasis Ulcers

Summary: fgf-1 is being used for the treatment of patients with diabetic or venous stasis ulcers. procedure includes topical administration of fgf-1 or placebo and evaluation of safety, pharmacokinetics, and wound improvement.

patients meeting eligibility criteria will be randomized to receive topical administration of either fgf-1 or placebo. patients will be evaluated at days 1 and 7, post-treatment for safety, pharmacokinetics, and wound healing.

Eligibility criteria:
eligibility criteria: * informed consent * female patients post-menopausal, sterilized, or on adequate birth control * full-thickness lower extremity diabetic or venous statis ulcers of specific target size and of at least 8 weeks but no more than 1 year duration * target ulcer freshly debrided at screening or within two weeks prior to screening * adequate blood supply defined by transcutaneous oxygen pressure \> 20 mmhg and abi greater than or equal to 0.4 * compliance with non-weight bearing regimen in diabetic patients * compliance with wound care regimen

Keywords: chronic wounds diabetes ulcers arterial bypass angioplasty diabetic ulcers
neonatal spinal muscular atrophy (sma) screening

Conditions: Spinal Muscular Atrophy

Summary: parents or legal guardian of neonates who signed agreement will receive sma screening test if their neonates are affected with sma. the dried blood spots of routine newborn screening samples will be used to test if neonates have lost 2 copies of smn1 gene. if neonates have positive sma screening test, further confirmation with multiplex ligation-dependent probe amplification (mlpa) test and prospective motor function monitoring including physical and neurological examinations will be proved to make sma confirmation. for any confirmed sma patient, genetic counseling and standard of care will be proved.


Eligibility criteria:
inclusion criteria: 1. neonates born in taiwan who receive regular newborn screening suggested by ministry of heath and welfare. 2. parents or legal guardian agree to perform sma newborn screening. exclusion criteria: parents or legal guardian do not agree to perform sma newborn screening.

Keywords: spinal muscular atrophy newborn screening
comparison of gait in syndesmosis injuries treated with screw fixation vs suture button

Conditions: Acute Disruption of Ankle Syndesmosis

Summary: injuries to the distal tibiofibular syndesmosis are common and occur in an estimated 25% of all rotational ankle fractures. anatomic reduction of the syndesmosis has been associated with improved functional outcome as well as decreased rates of posttraumatic arthritis. both screw fixation and suture fixation have become accepted standards of care for treatment of syndesmotic injuries. recent literature would suggest trends favoring suture fixation over screw fixation with improved quality of syndesmotic reduction, postoperative range of motion, and improved maintenance of syndesmotic reduction. however, the evidence remains heterogeneous, and patient reported outcomes have failed to show a superiority of one method over the other. additionally, there have been no studies that demonstrate objective gait outcomes comparing screw versus suture fixation for syndesmotic injuries.

this will be a prospective randomized study. patients with isolated rotational ankle injuries with syndesmotic instability will be randomized to either screw fixation or suture fixation for treatment of their syndesmotic injury. patients will be followed postoperatively for one year following surgery with documentation of both clinical outcomes and subjective patient reported outcomes. additionally, postoperative gait patterns will be measured and compared between patients who had syndesmotic injuries treated with screw fixation versus suture fixation

Eligibility criteria:
inclusion criteria: * adults 19 years of age and older. * isolated rotational ankle injury * syndesmotic instability (determined either pre- or intra-operatively) * length-stable fibula fracture pattern exclusion criteria: * open fracture * length-unstable fracture pattern (including maisonneuve fracture pattern) * syndesmotic stability (determined either pre- or intra-operatively) * lower extremity neuropathy * history of prior trauma or surgery to injured ankle * non-ambulatory patient * baseline use of ambulatory assistive device prior to injury
volume kinetics for hyperoncotic albumin in burn patients as well as for healthy subjects

Conditions: Burns

Summary: treatment with colloidal solutions has during long time been a cornerstone within intensive care. lately, doubts have been raised about synthetic colloids, and the natural albumin has been used more and more. one of these solutions is the hyperoncotic "albumin 20%". however there are still many aspects of the physiological effects of hyperoncotic albumin, that are not known. in this study physiological effects will be studied in burn patients and healthy subjects. the colloid osmotic pressure and the increase of the plasma volume will be measured in 15 healthy subjects and in 15 burn patients. the effect on the plasma volume will be studied using hemoglobin as a marker of dilution. colloids osmotic pressure and albumin concentration will be measured directly and urin production will also be measured. blood samples will be collected during 4 to 5 hours to achieve a profile over the changes.

healthy individuals are asked to refrain from eating and drinking the night before the study. two hours before study start, the subjects may take a sandwich and a glas to drink. patients will also be asked to keep the same rules unless they receive parenteral nutrition. shortly before the study, the subjects are asked to leave an urine sample. after 15 minutes of rest the first bood samples are taken. an infusion 3 ml/kg bodyweight albumin 20% is given during 30 minutes. the first hour after study start (start of infusion) blood samples are taken every 10 minutes. the following 4 hours another 9 blood samples are collected. hemoglobin, albumin and colloidosmotic pressure will be measured at every occasion. c-reactive protein, interleukin-6, syndecan -1 as well as heparan sulfate, will be measured before, after 1 hour and 5 hours after study start. the total volume of blood collected will be 150 ml. if the study subjects have a low urin output, acetated ringers will be given at the end of the study. liberal fluid intake is recommended the same day and the next.

Eligibility criteria:
inclusion criteria: * for healthy individuals: healthy, without allergies and with the age of 18 years or above. * for patients: burn injury exceeding 6-8 total burned surface area % exclusion criteria: * heart failure * signs of kidney injury/failure * severe allergies